Lp(a) Taskforce Logo

The Lp(a) International Taskforce

Advancing policy integration and scientific alignment for a major inherited cardiovascular risk factor

Lipoprotein(a), or Lp(a), is a causal and genetically determined driver of atherosclerotic cardiovascular disease, affecting approximately one in five individuals globally. Despite its high prevalence and well-established clinical relevance, Lp(a) remains systematically underdiagnosed and insufficiently addressed in both health policy and routine clinical practice.

Lp(a) is besides LDL-cholesterol clearly the next target to fight cardiovascular disease. The resulting efforts do not begin with the introduction of specific Lp(a)-lowering drugs, but with intensified efforts to treat any risk factors that may be present when a person has high Lp(a) levels. It, so to speak, paves the way for the necessary intensification of our efforts. And it involves the family due to its strong inheritance."

Prof. Florian Kronenberg Chair of the Lp(a) International Taskforce

About the Taskforce

The Lp(a) International Taskforce (ITF), established by the FH Europe Foundation, is a multidisciplinary initiative designed to bridge the persistent gap between scientific evidence and real-world implementation. It operates at the intersection of research, policy, and healthcare delivery, with the objective of ensuring that Lp(a) is appropriately recognised, measured, and managed within cardiovascular prevention strategies.

Formed in response to growing scientific consensus and increasing policy momentum, the Taskforce provides a coordinated platform to align stakeholders and support the integration of Lp(a) into national and international health frameworks.

Strategic Priorities of the Taskforce

The work of the Taskforce is structured around a set of interrelated priorities aimed at enabling systemic change:

Integration of Lp(a) testing into routine practice, supported by policies that promote standardised and accessible measurement.

Ensuring that Lp(a) is consistently reflected in policy and clinical frameworks, including guidelines, risk assessment models, and public health strategies.

Generation and translation of evidence, particularly in relation to epidemiology, clinical outcomes, and health economics.

Addressing health system readiness, recognising that the anticipated arrival of targeted therapies will require coordinated planning.

Need for structured collaboration across stakeholders, ensuring that scientific, clinical, and policy perspectives are aligned and mutually reinforcing.

Important

Addressing Lp(a) requires a coordinated and forward-looking approach. Integrating Lp(a) into policy and practice is not only a scientific imperative, but also a strategic opportunity to enhance cardiovascular prevention and reduce long-term system burden.